EconoTimesRisers & Fallers

EconoTimesRisers & Fallers
Share

CAMBRIDGE, Mass., June 26, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in a Phase 1 trial aimed at further optimizing the surgical delivery of VY-AADC01 for advanced Parkinson’s disease. This...

BETHLEHEM, Pa., May 22, 2017 -- B. Braun Medical Inc. will showcase its portfolio of infusion pump products and integrated technologies, designed to help improve patient safety and outcomes, at the American Association of Critical-Care Nurses (AACN) National Teaching Institute & Critical Care Exposition, May 23-25, at the George R. Brown Convention...

BETHLEHEM, Pa., May 17, 2017 -- With a rich history of bringing new products and services to the home infusion market, B. Braun Medical Inc. will showcase its latest technology and innovation at this year’s National Home Infusion Association (NHIA) Conference & Exposition at the Hilton Orlando from May 22-25. Among B. Braun’s latest advancements at...

Wilmington, Delaware, United States, March 25, 2017 -- The report “World Intravenous (IV) Ibuprofen Market - Opportunities and Forecast 2022”, available on MarketIntelReports, estimates that the market will register a CAGR of 20% till 2022. Browse numerous Market Tables as well as Figures which are spread through 65 Pages and an in-depth TOC on the...

EconoTimesRisers & Fallers

 •  October 5, 2016

WIXOM, Mich., Oct. 04, 2016 -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that the Triferic Phase-1 Healthy...

EconoTimesRisers & Fallers

 •  March 15, 2016

WALTHAM, Mass., March 14, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is a substance P/neurokinin-1 (NK-1) receptor antagonist that...

EconoTimesRisers & Fallers

 •  January 29, 2016

JERSEY CITY, N.J., Jan. 28, 2016 -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified Infectious Disease Product (QIDP) designations for the intravenous (IV) formulation of SCY-078, SCYNEXIS’ novel antifungal product, for the indications...